Antibodies against epidermal growth factor receptor (EGFR)—cetuximab and panitumumab—
are widely used to treat colorectal cancer. Unfortunately, patients eventually develop …

Purpose: Patients with colorectal cancer who respond to the anti-EGFR antibody cetuximab
often develop resistance within several months of initiating therapy. To design new lines of …

We conducted a retrospective collaborative study to cytogenetically characterize splenic
marginal zone lymphoma (SMZL) and ascertain the prognostic value of chromosomal …

The effectiveness of targeted therapies with tyrosine kinase inhibitors in non-small-cell lung
cancer (NSCLC) depends on the accurate determination of the genomic status of the …

Introduction: Translocation of the anaplastic lymphoma kinase (ALK) gene is involved in the
tumorigenesis of a subset of non-small cell lung carcinomas (NSCLCs) and identifies …

Purpose: Met receptor phosphorylation is associated with poor prognosis in human small
cell lung cancer (SCLC). The aim of our work was to investigate the effects of hepatocyte …

This study aimed to correlate the frequency of somatic mutations in the IgVH gene and the
use of specific segments in the VH repertoire with the clinical and characteristic features of a …

CD133 has been associated with cell properties such as self renewal, migration and
vasculogenic mimicry, potentially involved in generation of circulating tumor cells (CTCs) …

Introduction Increasing evidence supports the view that the detection of circulating tumor
cells (CTCs) predicts outcomes of nonmetastatic breast cancer patients. CTCs differ …

Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that
remain ineffective in a proportion of patients. Whether and how non-curative DNA damage …